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ABSTRACT. In the manufacture of universal peptide vaccines, it is necessary to analyze the amino acids 
of the various candidates. Therefore, this study aims to examine the amino acids of the spike glycoproteins 
of SARS-CoV, SARS-CoV-2, and MERS CoV. The method used is the alignment of the amino acid spike 
glycoprotein between SARS-CoV with SARS-CoV-2, MERS CoV with SARS-CoV-2, and SARS-CoV 
with MERS-CoV using web-based software water emboss. The analysis result showed that SARS and 
SARS CoV-2 were very similar with 87% similarity and 76.4% identity values. In contrast, SARS CoV-2 
with MERS and SARS with MERS were very different, having similarity and identity values less than 70%. 
Therefore, it is reasonable to conclude that spike glycoprotein's peptide is only useful from attacks by the 
SARS-CoV and SARS-CoV-2 viruses. 
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INTRODUCTION 
Coronavirus is 65 to 125 nm in size and as 
a single-stranded RNA virus, it has the length 
of 26-32 kbp. Furthermore, it consists of four 
subfamilies of alpha (α), beta (β), gamma (ϒ), 
and delta (δ) (Shereen et al., 2020). Before now, 
the virus only infected animals, however, in the 
2000s, there were known cases of SARS 
(Severe Acute Respiratory Syndrome), MERS 
(Middle East Respiratory Syndrome), and 
COVID-19 (Coronavirus Disease-2019) (Wang 
et al., 2013; Shereen et al., 2020). The 
Coronaviruses that cause SARS, MERS and 
COVID-19 are known as SARS-CoV (SARS-
coronavirus), MERS CoV (MERS-
coronavirus) and SARS CoV 2 (COVID-19) 
respectively. 
SARS-CoV is an etiologic agent of acute 
respiratory syndrome (Liu et al., 2014), and was 
endemic in 2002-2003 (Peiris et al., 2003). 
MERS (Middle East Respiratory Syndrome) is 
an infectious disease caused by the MERS virus 
(MERS-CoV), and it has similar symptoms 
with SARS, that cause flu-like illnesses which 
is respiratory tract disruption (da Costa et al., 
2020; Li et al., 2020). Both belong to the genus 
Betacoronavirus (Schoeman & Fielding, 2019; 
ICTV, 2020). Initially, MERS-CoV case was 
first identified in Saudi Arabia in September 
2012 by camel-to-human transmission, and 
then by human-to-human transmission (Jeong 
et al., 2017) and spread to countries in the 
Middle East (Zumla et al., 2015), precisely in 
the Arabian Peninsula and its surroundings 
such as the United Arab Emirates, Qatar, Oman, 
Jordan, Kuwait, Yemen, Iran, Egypt, and 
Lebanon (Rampengan, 2016; Shapiro et al., 
2016; WHO, 2016). Importations of MERS had 
been reported in France (Mailles et al., 2013; 
Puzelli et al., 2013), Italy (Puzelli et al., 2013), 
Spain (Rashid et al., 2013), United Kingdom 
(Thomas et al., 2014), Tunisia (Abroug et al., 
2014), Malaysia (Cunha & Opal, 2014), 
Philippines (Racelis et al., 2015), and Korea 
(Jeong et al., 2017) in the following years. The 
SARS-CoV-2 attack resurfaced at the end of 
2019 in Wuhan, China, and has spread to almost 
all countries worldwide, and this condition was 
given the term COVID-19 (Corona Virus 
Disease-2019) (ICTV, 2020).  
Vaccines for MERS, SARS and COVID-19 
are yet to be discovered (Slamet et al., 2013) but 
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the process continues to experience 
development. In addition, it consists of several 
amino acid residues (small proteins) (Subroto et 
al., 2013) and with the existence, it is possible 
to make a universal vaccine. This can serve a 
protective function against various types of 
antigens, which is primarily used for making 
peptide vaccines. Therefore, a strong similarity 
protein is needed to make a universal vaccine 
against coronaviruses (SARS, MERS and 
COVID-19) (Alouane et al., 2020; Khalaj-
Hedayati, 2020; Wu et al., 2020). 
There have been many research related to 
the manufacture of vaccine candidates, one of 
which is the HPV (Human Papillomavirus). 
This study shows that the promising vaccine 
peptide candidate of the E1 protein obtained 
from HPV genome is LLITSNINA, from E5 is 
VLLCVCLLI and from E7 is LLMGTLGIV 
(Aprilyanto & Sembiring, 2017). Furthermore, 
they have been tested in vitro, and the results 
are useful in activating the immune response. 
One of the conditions for making a peptide 
vaccine is that the protein antigen should be 
located at the outer part of the virus in order to 
ease the purification process. The spike 
glycoprotein is used as a peptide vaccine 
candidate since its position is in the outer part, 
and it is possessed by all types of Coronavirus. 
Therefore, this protein is used as a candidate 
source for peptide vaccines for all kinds of 
Coronavirus.  
Initially, the research was conducted to 
obtain an overview of its potential as a vaccine 
candidate. In addition, an explanation of their 
potential will be obtained by testing the 
similarity and identity for the amino acid 
sequence of spike glycoproteins. 
 
MATERIALS AND METHODS 
This research used the following materials; 
amino acid sequence of SARS-CoV-2, SARS-
CoV (SARS), and MERS-CoV (MERS) spike 
glycoprotein with NCBI having the Accession 
Number YP_009724390.1 (COVID-19), 
P59594, and A0A140AYZ5 respectively. 
Work Procedures. This research was 
conducted in the following stages: SARS CoV-
2 (COVID-19) spike glycoprotein downloaded 
at https://www.ncbi.nlm.nih.gov/; SARS CoV 
spike glycoprotein downloaded at 
http://www.uniprot.org; MERS spike 
glycoprotein download at 
http://www.uniprot.org; alignment process 
between spike glycoproteins of COVID-19 
with SARS in the 
https://www.ebi.ac.uk/Tools/psa/emboss_wate
r/program; alignment between spike 
glycoproteins of COVID-19 with MERS in the 
https://www.ebi.ac.uk/Tools/psa/emboss_wate
r/ program; alignment between spike 





RESULTS AND DISCUSSION 




# Program: water 
# Aligned_sequences: 2 
# 1: YP_009724390. (SARS CoV-2/Covid-19) 
# 2: SPIKE_CVHSA   (SARS) 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# Length: 1277 
# Identity:     975/1277 (76.4%) 
# Similarity:  1111/1277 (87.0%) 
# Gaps:          26/1277 (2.0%) 
# Score: 5230.0 
#======================================= 
YP_009724390.      1 MFVFLVLLPLVS-SQCVNLTTRTQL-PPAYT--NSFTRGVYYPDKVFRSS     46 
                     ||:||:.|.|.| |.....||...: .|.||  .|..|||||||::|||. 
SPIKE_CVHSA        1 MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSD     50 
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YP_009724390.     47 VLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTE     96 
                     .|:.||||||||:||||.||.|     |.|  |.|||:||.||:|||:|| 
SPIKE_CVHSA       51 TLYLTQDLFLPFYSNVTGFHTI-----NHT--FGNPVIPFKDGIYFAATE     93 
 
YP_009724390.     97 KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYH    146 
                     |||::|||:||:|:::|:||::|:||:|||||:.|.|:.|::||..|    
SPIKE_CVHSA       94 KSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFAV---    140 
 
YP_009724390.    147 KNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKN    196 
                      :.....::...::.:|.||||||:|..|.:|:..|.||||:|||||||| 
SPIKE_CVHSA      141 -SKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKN    189 
 
YP_009724390.    197 IDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHR    246 
                     .||:..:|..:.||::|||||.||:.|:|:..||:|||||.|:.:|     
SPIKE_CVHSA      190 KDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLPLGINITNFRAIL----    235 
 
YP_009724390.    247 SYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPL    296 
                     :..:|....  |...||||:||||:|.||:|||:|||||||||||:.:|| 
SPIKE_CVHSA      236 TAFSPAQDI--WGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPL    283 
 
YP_009724390.    297 SETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATR    346 
                     :|.||::|||.::|||||||||||.|:..:|||||||||||||||||||: 
SPIKE_CVHSA      284 AELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATK    333 
 
YP_009724390.    347 FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVY    396 
                     |.|||||.||:||||||||||||||..||||||||||.||||||||:||| 
SPIKE_CVHSA      334 FPSVYAWERKKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVY    383 
 
YP_009724390.    397 ADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVG    446 
                     |||||::||:||||||||||.||||||||||||.|||:|||:.|:|:... 
SPIKE_CVHSA      384 ADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATST    433 
 
YP_009724390.    447 GNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYG    496 
                     |||||.||..|...|:|||||||...:.....||. ....|||:||..|| 
SPIKE_CVHSA      434 GNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCT-PPALNCYWPLNDYG    482 
 
YP_009724390.    497 FQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGL    546 
                     |..|.|:|||||||||||||||:|||||||||.||:|:||:||||||||| 
SPIKE_CVHSA      483 FYTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGL    532 
 
YP_009724390.    547 TGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVS    596 
                     |||||||.|:|:|.||||||||::|.||:||||:|.|||||:|||||||| 
SPIKE_CVHSA      533 TGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVS    582 
 
 
YP_009724390.    597 VITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTR    646 
                     |||||||.|::|||||||||||:|..|||||||||.||:||||:|||||: 
SPIKE_CVHSA      583 VITPGTNASSEVAVLYQDVNCTDVSTAIHADQLTPAWRIYSTGNNVFQTQ    632 
 
YP_009724390.    647 AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYT    696 
                     ||||||||||:.||||||||||||||||.|.:    ..||.:.:||:||| 
SPIKE_CVHSA      633 AGCLIGAEHVDTSYECDIPIGAGICASYHTVS----LLRSTSQKSIVAYT    678 
 
YP_009724390.   1247 CCSCGSCCKFDEDDSEPVLKGVKLHYT   1273 
                     .|||||||||||||||||||||||||| 
SPIKE_CVHSA     1229 ACSCGSCCKFDEDDSEPVLKGVKLHYT   1255 
 
Fig. 1. Alignment result between SARS CoV-2 with SARS-CoV spike glycoproteins. 
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Alignment result between COVID-19 with MERS  
######################################## 
# Program: water 
# Aligned_sequences: 2 
# 1: YP_009724390.1   (Covid-19) 
# 2: A0A140AYZ5_9BETC (MERS) 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# 
# Length: 1440 
# Identity:     433/1440 (30.1%) 
# Similarity:   654/1440 (45.4%) 
# Gaps:         276/1440 (19.2%) 
# Score: 1565.5 
#======================================= 
YP_009724390.      3 VFLVLLPL-------------VSSQCVNLTTRTQL-----PPAYTNSFTR     34 
                     |||::..|             |.|.|:.:..:...     |.....|... 
A0A140AYZ5_9B      5 VFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFFDKTWPRPIDVSKAD     54 
 
YP_009724390.     35 GVYYPDKVFRSSVLHSTQDLFLPF---FSNVTWFHAIHVSGTNGTKRF--     79 
                     |:.||.....|::..:.|.|| |:   ..::..:.|.|.:||...|.|   
A0A140AYZ5_9B     55 GIIYPQGRTYSNITITYQGLF-PYQGDHGDMYVYSAGHATGTTPQKLFVA    103 
 
YP_009724390.     80 --DNPVLPF-------------NDGVYFASTEKSNIIR--------GWIF    106 
                       ...|..|             :.|....|...|..||        |... 
A0A140AYZ5_9B    104 NYSQDVKQFANGFVVRIGAAANSTGTVIISPSTSATIRKIYPAFMLGSSV    153 
 
YP_009724390.    107 GTTLDSK-----TQSLLIVNNATNVVIKVCEFQFCNDPFLGVY-------    144 
                     |...|.|     ..:|:::.:....:::.  |....:|..|.:        
A0A140AYZ5_9B    154 GNFSDGKMGRFFNHTLVLLPDGCGTLLRA--FYCILEPRSGNHCPAGNSY    201 
 
YP_009724390.    145 -----YH---------KNNKSWMESEFRVYSSANNCTFEY---VSQPFLM    177 
                          ||         ..|::...:.|:.|.:..||||.|   :::..:: 
A0A140AYZ5_9B    202 TSFATYHTPATDCSDGNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEIL    251 
 
YP_009724390.    178 DLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLV    227 
                     :..|.....:.:..|..:.:|.|                            
A0A140AYZ5_9B    252 EWFGITQTAQGVHLFSSRYVDLY---------------------------    274 
 
 
YP_009724390.    228 DLPIGINITRFQTL---------LALHRSYLTPGDSSSGWTAGAAAYYVG    268 
                         |.|:.:|.||         ..:..|..:.......|    ||:||. 
A0A140AYZ5_9B    275 ----GGNMFQFATLPVYDTIKYYSIIPHSIRSIQSDRKAW----AAFYVY    316 
 
YP_009724390.    269 YLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNF    318 
                     .|||.||||.::.:|.|..|:||..:.||:..|:.:||.||.|:|..|:| 
A0A140AYZ5_9B    317 KLQPLTFLLDFSVDGYIRRAIDCGFNDLSQLHCSYESFDVESGVYSVSSF    366 
 
YP_009724390.    319 RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVL    368 
                     ..:|:.|:|....... |.|..:.:.|. ..||.:.|...:||..:.:.| 
A0A140AYZ5_9B    367 EAKPSGSVVEQAEGVE-CDFSPLLSGTP-PQVYNFKRLVFTNCNYNLTKL    414 
 
YP_009724390.    369 YNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKI    418 
                     .:..|.:.|.|..:||..:...|::::..|.|.........::....|.| 
A0A140AYZ5_9B    415 LSLFSVNDFTCSQISPAAIASNCYSSLILDYFSYPLSMKSDLSVSSAGPI    464 
 
YP_009724390.    419 ADYNYKLPDDFTGC-VIAWNSNNLDSKVGG-NYNYLYRLFRKSNLKPFER    466 
                     :.:|||.......| ::|...:||.:.... .|:|:.:..|..:       
A0A140AYZ5_9B    465 SQFNYKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRLLS------    508 
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YP_009724390.    467 DISTEIYQAGS----TPCNGV------EGFNCY----FPLQSYGFQPTNG    502 
                     |..||:.|..:    :||...      |..:.|    .||:..|:...:| 
A0A140AYZ5_9B    509 DDRTEVPQLVNANQYSPCVSTVPSTVWEDGDYYRKQLSPLEGGGWLVASG    558 
 
YP_009724390.    503 VGYQPYRVVVLSFELLHAPAT----VCGPKKSTNLVK-----NKCVNFNF    543 
                     ........:.:.|.:.....|    ||...:..|..|     ..||.::. 
A0A140AYZ5_9B    559 STVAMTEQLQMGFGITVQYGTDTNSVCPKLEFANDTKIASQLGNCVEYSL    608 
 
YP_009724390.    544 NGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG    593 
                     .|::|.||........:..|:|      ..||.:                 
A0A140AYZ5_9B    609 YGVSGRGVFQNCTAVGVRQQRF------VYDAYQ----------------    636 
 
YP_009724390.   1175 SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGL   1224 
                     :::::..|:..|.:|.|.||||.|||:|||.|..|.|||||||||||||| 
A0A140AYZ5_9B   1258 TLLDLTYEMLSLQQVVKALNESYIDLKELGNYTYYNKWPWYIWLGFIAGL   1307 
 
YP_009724390.   1225 IAIVMVTIMLCCMTSCCSCLKGCCSCGSCC-KFDEDDSEP   1263 
                     :|:.:....:.|.|.|.:...|...|..|| :::|.|.|| 
A0A140AYZ5_9B   1308 VALALCVFFILCCTGCGTNCMGKLKCNRCCDRYEEYDLEP   1347 
Fig. 2. Alignment Result between SARS CoV-2 with MERS CoV Spike Glycoproteins. 
Alignment result between SARS with MERS spike glycoproteins 
######################################## 
# Program: water 
# Aligned_sequences: 2 
# 1: SPIKE_CVHSA      (SARS) 
# 2: A0A140AYZ5_9BETC (MERS) 
# Matrix: EBLOSUM62 
# Gap_penalty: 10.0 
# Extend_penalty: 0.5 
# Length: 1400 
# Identity:     443/1400 (31.6%) 
# Similarity:   662/1400 (47.3%) 
# Gaps:         214/1400 (15.3%) 
# Score: 1561.0 
#======================================= 
SPIKE_CVHSA        3 IFLLFLTLTS-------GSD--------LDRCTTFDDVQAPNYTQHTSSM     37 
                     :|||...||.       |.|        :|...||.|...|.... .|.. 
A0A140AYZ5_9B      5 VFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFFDKTWPRPID-VSKA     53 
 
SPIKE_CVHSA       38 RGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFGNPVIPFKDGI     87 
                     .|:.||.....|:.....|.|| |:..:....:..:........|.|    
A0A140AYZ5_9B     54 DGIIYPQGRTYSNITITYQGLF-PYQGDHGDMYVYSAGHATGTTPQK---     99 
 
SPIKE_CVHSA       88 YFAATEKSNV---VRGWV--FGSTMNNKSQSVIIINNSTNVVIRACNFEL    132 
                     .|.|....:|   ..|:|  .|:..|  |...:||:.||:..||..     
A0A140AYZ5_9B    100 LFVANYSQDVKQFANGFVVRIGAAAN--STGTVIISPSTSATIRKI----    143 
 
SPIKE_CVHSA      133 CDNPFFAVSKPMGTQT---------HTMIF--D------NAFNCTFE---    162 
                       .|.|.:...:|..:         ||::.  |      .||.|..|    
A0A140AYZ5_9B    144 --YPAFMLGSSVGNFSDGKMGRFFNHTLVLLPDGCGTLLRAFYCILEPRS    191 
 
SPIKE_CVHSA      163 ---------YISDAF----SLDVSEKSGNFKH------LREFVFKNKDGF    193 
                              |.|.|.    :.|.|:  ||:..      .:|:.......| 
A0A140AYZ5_9B    192 GNHCPAGNSYTSFATYHTPATDCSD--GNYNRNASLNSFKEYFNLRNCTF    239 
 
SPIKE_CVHSA      194 LYVY--------------KGYQPIDVVR----DLPSG----------FNT    215 
                     :|.|              :..|.:.:..    ||..|          ::| 
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A0A140AYZ5_9B    240 MYTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDT    289 
 
SPIKE_CVHSA      216 LKPIFKLPLGINITNFRAILTAFSPAQDIWGTSAAAYFVGYLKPTTFMLK    265 
                     :|....:|..|.         :....:..|    ||::|..|:|.||:|. 
A0A140AYZ5_9B    290 IKYYSIIPHSIR---------SIQSDRKAW----AAFYVYKLQPLTFLLD    326 
 
SPIKE_CVHSA      266 YDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVR    315 
                     :..:|.|..|:||..|.|::|.||.:||:::.|:|..|:|...|||.||. 
A0A140AYZ5_9B    327 FSVDGYIRRAIDCGFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVE    376 
 
SPIKE_CVHSA      316 FPNITNLCPFGEVFNATKFPSVYAWERKKISNCVADYSVLYNSTFFST--    363 
                     ...... |.|..:.:.|. |.||.::|...:||  :|::....:.||.   
A0A140AYZ5_9B    377 QAEGVE-CDFSPLLSGTP-PQVYNFKRLVFTNC--NYNLTKLLSLFSVND    422 
 
SPIKE_CVHSA      364 FKCYGVSATKLNDLCFSNVYADSF----VVKGDDVRQIAPGQTGVIADYN    409 
                     |.|..:|...:...|:|::..|.|    .:|.|    ::....|.|:.:| 
A0A140AYZ5_9B    423 FTCSQISPAAIASNCYSSLILDYFSYPLSMKSD----LSVSSAGPISQFN    468 
 
SPIKE_CVHSA      410 YKLPDDFMGC-VLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNV    458 
                     ||.......| :||....|:   :|.....||.|:.... |....|.:.| 
A0A140AYZ5_9B    469 YKQSFSNPTCLILATVPHNL---TTITKPLKYSYINKCS-RLLSDDRTEV    514 
 
SPIKE_CVHSA      459 PFSPDG---KPCTPPALNCYWPLNDY-----------GFYTTTGIGYQPY    494 
                     |...:.   .||.....:..|...||           |:...:|...... 
A0A140AYZ5_9B    515 PQLVNANQYSPCVSTVPSTVWEDGDYYRKQLSPLEGGGWLVASGSTVAMT    564 
 
SPIKE_CVHSA      495 RVVVLSFELLNAPAT----VCGPKL---STDLIKNQ---CVNFNFNGLTG    534 
                     ..:.:.|.:.....|    || |||   :...|.:|   ||.::..|::| 
A0A140AYZ5_9B    565 EQLQMGFGITVQYGTDTNSVC-PKLEFANDTKIASQLGNCVEYSLYGVSG    613 
 
SPIKE_CVHSA      535 TGVL---TPSSKRFQPF--QQFGRDVSDFTDSVRDPKTSEILDISPCSFG    579 
                     .||.   |....|.|.|  ..:...|..::|.      .....:..|... 
A0A140AYZ5_9B    614 RGVFQNCTAVGVRQQRFVYDAYQNLVGYYSDD------GNYYCLRACVSV    657 
 
SPIKE_CVHSA      580 GVSVITPGTNASSEVAVLYQDVNCTDVSTAIHADQLTPAWR-IYSTGNNV    628 
                     .||||.  ...:...|.|:..|.|..:|:.:  .|.:.:.| :....::. 
A0A140AYZ5_9B    658 PVSVIY--DKETKTHATLFGSVACEHISSTM--SQYSRSTRSMLKRRDST    703 
 
SPIKE_CVHSA      629 F---QTQAGCLIGAEHVDTSY---ECDIPIGAGICASYHTVSLLRSTSQK    672 
                     :   ||..||::|.  |::|.   :|.:|:|..:||...|.|.|...|.: 
A0A140AYZ5_9B    704 YGPLQTPVGCVLGL--VNSSLFVEDCKLPLGQSLCALPDTPSTLTPRSVR    751 
 
SPIKE_CVHSA      673 SI--------VAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMA    714 
                     |:        :|:...:..| .:..|...::||||||..:|.|.:..::. 
A0A140AYZ5_9B    752 SVPGEMRLASIAFNHPIQVD-QLNSSYFKLSIPTNFSFGVTQEYIQTTIQ    800 
 
SPIKE_CVHSA      715 KTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVF    764 
                     |.:|||..|:|....:|..||.:||.||:::|:||.|....||.:.|.:| 
A0A140AYZ5_9B    801 KVTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSVRNLF    850 
 
SPIKE_CVHSA      765 AQVKQMYKTPTLKYFGG-FNFSQILPDPLKP---TKRSFIEDLLFNKVTL    810 
                     |.||....:|.:..||| ||.:.:.|..:..   :.||.||||||:|||: 
A0A140AYZ5_9B    851 ASVKSSQSSPIIPGFGGDFNLTLLEPVSISTGSRSARSAIEDLLFDKVTI    900 
 
SPIKE_CVHSA      811 ADAGFMKQYGECL--GDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAA    858 
                     ||.|:|:.|.:|:  |..:||||||||...|..|||||:..:|.||||:: 
A0A140AYZ5_9B    901 ADPGYMQGYDDCMQQGPASARDLICAQYVAGYKVLPPLMDVNMEAAYTSS    950 
 
SPIKE_CVHSA      859 LVSGTATAGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQ    908 
                     |:...|..|||.|..:...||||..:.||.||:|:||.||.||||.|||: 
A0A140AYZ5_9B    951 LLGSIAGVGWTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSENQKLIANK   1000 
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SPIKE_CVHSA      909 FNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSV    958 
                     ||:|:..:|...|||:.|..|:||.||.|||||:.|..:||:.|||||:. 
A0A140AYZ5_9B   1001 FNQALGAMQTGFTTTNEAFRKVQDAVNNNAQALSKLASELSNTFGAISAS   1050 
 
SPIKE_CVHSA      959 LNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAA   1008 
                     :.||:.|||.:|.:.||||||.|||.:|..:|.|||:|:.....||.||. 
A0A140AYZ5_9B   1051 IGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLAK   1100 
 
SPIKE_CVHSA     1009 TKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFT   1058 
                     .|::|||..||||..|||:|.|::||...||:|:.|:||.|.||...... 
A0A140AYZ5_9B   1101 DKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIEVV   1150 
 
SPIKE_CVHSA     1059 TAPAIC---HEGKAYFPREGVFV-FNGT----SWFITQRNFFSPQIITTD   1100 
                     :|..:|   :......|..|.|: .|.|    .|..|..:|::|:.||:. 
A0A140AYZ5_9B   1151 SAYGLCDAANPTNCIAPVNGYFIKTNNTRIVDEWSYTGSSFYAPEPITSL   1200 
 
SPIKE_CVHSA     1101 NT-FVSGNCDVVIGIINNTVYDPL---QPELDSFKEELDKYFKNHTSPDV   1146 
                     || :|:.  .|....|:..:..||   ...:| |::|||::|||.::... 
A0A140AYZ5_9B   1201 NTKYVAP--QVTYQNISTNLPPPLLGNSTGID-FQDELDEFFKNVSTSIP   1247 
 
SPIKE_CVHSA     1147 DLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPW   1196 
                     :.|.::.||.:::::..|:..|.:|.|.||||.|||:|||.|..|.|||| 
A0A140AYZ5_9B   1248 NFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYTYYNKWPW   1297 
 
SPIKE_CVHSA     1197 YVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCC-KFDEDDSEP   1245 
                     |:||||||||:|:.:....:.|.|.|.:...|...|..|| :::|.|.|| 
A0A140AYZ5_9B   1298 YIWLGFIAGLVALALCVFFILCCTGCGTNCMGKLKCNRCCDRYEEYDLEP   1347 
Fig. 3. Alignment result between MERS CoV with SARS CoV spike glycoproteins. 
Table 1 represents the results of the 
alignment shown by the value of identity and 
similarity. The Identity is the percentage of 
identical matches between the two sequences 
over the reported aligned region (including any 
gaps in the length). The following are the 
results of alignment among the three viruses. 
 
Table 1. Conclusions on the alignment results of the 
coronavirus spike glycoprotein. 




1 Covid-19 x SARS 76.4 87.0 
2 Covid-19 x MERS 30.1 45.4 
3 SARS x MERS 31.6 47.3 
 
The similarity is the percentage of matches 
between the two sequences over the reported 
aligned region (including any gaps in the 
length) (Taupiqurrohman et al., 2016). In 
addition, Identity value indicates the identical 
equation of the compared amino acids, while 
the similarity value indicates the conformity on 
chemical properties (Hui et al., 2020). Table 1 
also shows that Coronaviruses of SARS and 
COVID-19 have a high similarity with an 
identity value of 76.4% and 87%. On the 
contrary, the comparison of MERS and 
COVID-19 is relatively not similar because the 
alignment results are below 70%. The low 
result is also shown by the comparison between 
SARS with MERS having 31.6% identity, and 
47.3% similarity. This is consistent with the 
explanation of Andriani (2016) and Li et al. 
(2020), where it was stated that the 
coronaviruses of SARS and COVID-19 are 
very close based on evolution tree. According 
to Rice et al. (2000), phylogenetic results 
(evolutionary kinship) cannot be concluded 
because of the type of protein being compared. 
Therefore, this research has illustrated the great 
potential of spike glycoprotein to be the source 
of peptide vaccine candidates for the SARS and 
COVID-19 diseases. Below is the structure of 
the spike glycoprotein of SARS-CoV, SARS-
CoV-2, and MERS based on the database 
(pdb.org). 
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Fig. 5. Structure of SARS CoV-2 spike glycoproteins. 
 
 
Fig. 6. Structure of SARS CoV spike glycoproteins 
 
Work Principles of Universal Peptide 
Vaccine. The sequential analysis shows that 
spike glycoprotein can only be used as the 
source of peptide vaccine candidates for SARS 
and COVID-19. This should be properly 
conducted since the working principle of 
peptide vaccine is based on the immune system. 
The two common parts when a virus infects are 
the outside (specific body tissue) and the inside 
of an infected cell (body cell). When a part of 
the tissue is infected, the immune cells in the 
region begin to respond (Mothes et al., 2010; 
Mallapaty, 2020). This is evident in 
macrophages, which is one type of immune cell 
that is responsible for initiating the formation of 
antibodies through the activation of helper T 
cells. To activate this cells, macrophages will 
phagocytize the incoming antigen protein. 
Furthermore, the results of phagocytosis (small 
peptides) are raised to the surface of the body 
by major histocompatibility (MHC) class II 
protein to be recognized by helper T cell 
receptors (Li et al., 2020). Andriani (2016) 
stated the predicted part and made into a peptide 
vaccine. 
During an internal cellular infection, the 
cell responds through a series of reactions (Fig. 
4). An important part of this response in relation 
to the peptide vaccine is that the cell will 
attempt to bring the virus part to the surface. 
This is conducted by the MHC class I and 
recognized by cytotoxic T cells, which 
functions to reduce infection (Li et al., 2020). 
The part of the virus raised by MHC I and II is 
another peptide vaccine candidate that is 
predicted by using the spike glycoprotein 
(marked in the box in the picture). This protein 
is a potential candidate for peptide vaccine 
since it is found on the outer part of the virus 
spike glycoprotein is also in the outer part of the 
virus, thus it is a potential candidate for peptide 
vaccine. Initially, it is recognized or attached to 
the cell surface, and the location is given below. 
Every disease has a cure. If the right 
medicine is found for a disease, the disease will 
be cured with the permission of Allah Azza wa 
Jalla (Sahih Muslim No. 4084). Based on this 
hadith, we can learn that there is no disease on 
this earth that was created by Allah swt. without 
a cure. As at present, many kinds of research 
have been carried out by scientists to find the 
most appropriate vaccine candidates for use in 
the prevention of infectious diseases caused by 
the coronavirus. The success of finding a 
vaccine candidate with the highest level of 
effectiveness is also inseparable from the power 
of Allah Almighty, as His word in QS. Ash-
Shu'ara verse 80 (Kementerian Agama RI, 
2019). This verse explains that it is Allah swt. 
who heals a man when he is sick. Allah has the 
power to heal any disease that a person has. But 
man, through the use of the mind by studying 
science, must also find out how to obtain this 
healing. Through science, humans can find out 
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the types of amino acids from the glycoprotein 
spike of various types of coronaviruses that are 
most appropriate to be used in the production of 
universal peptide vaccines for various types of 
infectious diseases caused by various types of 
coronaviruses. The lesson that can be taken 
from this verse is that diseases experienced by 
humans are the result of human actions 
themselves, including infection with diseases 
caused by the coronavirus, one of which is the 
lack of a clean lifestyle. Through the efforts 
made by humans and by the will of Allah swt. 
diseases suffered by humans can be cured. 
Diseases that occur in humans can also be a 
reminder to always be grateful for the various 
blessings from Allah swt. One of which is the 
favor of healing from an illness. 
 
CONCLUSION 
SARS CoV-2 (COVID-19) and SARS are 
very similar with 87% similarity and 76.4% 
identity values. In contrast, covid-19 with 
MERS and SARS with MERS are very 
different because of their reduced similarity and 
identity values below 70%. Therefore, the spike 
glycoprotein can only be used as the peptide 
vaccine candidate for COVID-19 and SARS. 
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